Refine Results
- 必威体育赛事投注
- Content Type
-
Content Type
- Analysis Platform
-
Product
- Language
-
Language
Applied Filters
In this application note, Antibody Analytics (Motherwell, UK) integrates IndEx-2, an advanced in vitro cell-based platform engineered to modulate the expression of one or two target antigens across a range of biologically relevant levels, with the...
- Publication Part Number: 5994-7175EN
- Created: 06 June 2024
- 2 MB
必威体育登录手机A 45-color spectral flow cytometry panel was designed for the Agilent NovoCyte Opteon spectral flow cytometer to analyze the distribution of immune cells.
- Publication Part Number: 5994-7397EN
- Created: 30 May 2024
- 8 MB
Chinese (Simplified) (China) | Complete (PDF) |
---|---|
Japanese (Japan) | Complete (PDF) |
Korean (Korea) | Complete (PDF) |
This application note describes a novel real-time co-culture assay using RTCA eSight for interrogating NK92 immune cell invasion and cytotoxicity and migratory kinetic profiles based on ECM and effects of TME.
- Publication Part Number: 5994-6888EN
- Created: 29 Nov 2023
- 3 MB
必威体育登录手机This application note evaluates the Agilent xCELLigence RTCA eSight as a tool to monitor BiTE antibody-mediated cancer cell lysis.
- Publication Part Number: 5994-6004EN
- Created: 21 Apr 2023
- 2 MB
必威体育登录手机Comprising instruments, assay kits, software, and consumables, Agilent Seahorse XF platforms are designed to support you from sample to insight.
- Publication Part Number: 5994-1329EN
- Created: 18 July 2022
- 3 MB
Chinese (Simplified) (China) | Complete (PDF) |
---|---|
German (Germany) | Complete (PDF) |
Russian (Russia) | Complete (PDF) |
French (France) | Complete (PDF) |
xCELLigence Immunotherapy IMT Assay (anti-CD9) Tethering Kit and Sample Kit Protocol
- Publication Part Number: 5994-3234EN
- Created: 15 Mar 2022
- 634 KB
xCELLigence Immunotherapy IMT Assay (anti-CD19) Tethering Kit and Sample Kit Protocol
- Publication Part Number: 5994-3235
- Created: 14 July 2021
- 768 KB
xCELLigence Immunotherapy IMT Assay (anti-CD40) Tethering Kit and Sample Kit Protocol
- Publication Part Number: 5994-3238
- Created: 14 July 2021
- 727 KB
xCELLigence Immunotherapy IMT Assay (anti-CD71) Tethering Kit and Sample Kit Protocol
- Publication Part Number: 5994-3236
- Created: 14 July 2021
- 749 KB
xCELLigence Immunotherapy IMT Assay (anti-CD29) Tethering Kit and Sample Kit Protocol
- Publication Part Number: 5994-3237
- Created: 14 July 2021
- 671 KB
必威体育登录手机Using the Agilent xCELLigence RTCA eSight to continuously monitor CAR T cell-mediatedkilling of cancer cells over the course of multiplae days.
- Publication Part Number: 5994-1712EN
- Created: 09 Nov 2020
- 4 MB
Chinese (Simplified) (China) | Complete (PDF) |
---|
必威体育登录手机Using the Agilent xCELLigence RTCA system to assess both the selectivity and potency of the TCR-engineered TILs toward HLA restricted cells.
- Publication Part Number: 5994-1771EN
- Created: 25 Mar 2020
- 1 MB
Examines the phosphorylation of signal transducer and activator of transcription (STAT) proteins in response to cytokine stimulation using a phosphoflow technique.
- Publication Part Number: 5994-1030EN
- Created: 01 Nov 2019
- 1 MB
Real-time, kinetic measurements of functional metabolism in cells sourced from blood link mitochondrial function to disease diagnosis and progression.
- Publication Part Number: 5991-7123EN
- Created: 04 Jan 2017
- 643 KB
A real-time assay that quantifies the ATP and biosynthetic demands of immune cell proliferation, differentiation and effector function.
- Publication Part Number: 5991-7128EN
- Created: 22 Dec 2016
- 635 KB
This poster presents data that delayed killing of tumor cells in can be resolved using both impedance and imaging on RTCA eSight.
- Publication Part Number: AACR 2024 Poster 4699
- Created: 04 Apr 2024
- 767 KB
This editorial will discuss the potency assays available for cellular immunotherapies, the regulatory criteria they must meet, and the challenges faced in measuring immune cell cytotoxicity.
- Publication Part Number: 5994-7162EN
- Created: 15 Feb 2024
- 1 MB
Targeting the immune system has dramatically increased the need for tracking the native, and more recently, engineered phenotypes of multiple cell lineages.
- Publication Part Number: 5994-4703EN
- Created: 17 Aug 2022
- 798 KB
Although cell therapies have shown great promise in clinical studies, challenges with the large scale manufacturing of these therapies still need to be addressed.
- Publication Part Number: 5994-4702EN
- Created: 17 Aug 2022
- 721 KB
Cytotoxicity is not enough, in vitro assays must also assess persistence and durability.The great challenge of immune cell-based therapies is to safely engineer cells that have enhanced performance character
- Publication Part Number: 5994-4701EN
- Created: 17 Aug 2022
- 2 MB